BJH - volume 13, issue 4, june 2022
C. Vandenbriele MD, PhD, D.A. Gorog MD, PhD
COVID-19 is associated with pulmonary thromboembolism and deep venous thrombosis. Its prevalence increases in the intensive care unit and is especially high in patients on extracorporeal membrane oxygenation (ECMO). This literature review aimed to assess the usefulness of screening for peripheral venous thrombosis or pulmonary thrombosis in patients admitted with COVID-19. In the non-ICU setting, increased D-dimer levels from baseline indicate the need for Doppler ultrasound scan of the lower limbs. In the ICU setting, clinical features and D-dimer levels may not accurately reflect the occurrence of pulmonary thromboembolism. Therefore, it is necessary to increase vigilance for VTE, with a low threshold for Doppler ultrasound and CTPA in high-risk in-patient cohorts.
(BELG J HEMATOL 2022;13(4):145–8)
Read moreBJH - volume 12, issue 4, june 2021
C. Vandenbriele MD, PhD, L. Van der Linden PhD, PharmD, L.N.L. Van Aelst MD, PhD, B. Schwagten MD, PhD, F. van Heuverswyn MD, S. Meers MD, PhD, V. Galle MD, T. Van Nieuwenhuyse PharmD, K.L. Wu MD, PhD, M. André MD, PhD, C. Hermans MD, PhD, A. Janssens MD, PhD
Over the last decade, the oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib induced a paradigm shift in the treatment of patients with chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), and Waldenströms macroglobulinemia (WM). In clinical trials and in real-world studies, ibrutinib proved to be an effective agent with an overall favourable safety and tolerability profile. However, compared with standard chemo-immunotherapy (CIT), ibrutinib was associated with a higher incidence of atrial fibrillation (AF). The patho-physiological mechanisms underlying this increased AF incidence are not completely understood, but it is thought to be related to off-target inhibitory effects of ibrutinib on the Tec protein tyrosine kinase (TEC) in cardiac cells. The prevalence of AF in patients treated with ibrutinib is highest during the first three months of therapy, which warrants an increased vigilance during this treatment phase. However, AF in patients treated with ibrutinib is generally well manageable without ibrutinib discontinuation. Prior to the start of ibrutinib treatment, identification and addressing modifiable risk factors for AF is a first important step. The threshold for haematologists to consult a cardiologist or a cardio-oncologist should be low and a close collaboration between both specialties is warranted. Unnecessary ibrutinib interruptions should be avoided, and uncomplicated AF is not a valid reason to discontinue or interrupt ibrutinib. If anticoagulation is required, direct oral anticoagulants are preferred. In this paper, a panel of haematology and cardiology specialists have provided practical guidance on how to evaluate patients prior to ibrutinib treatment and monitor during ibrutinib therapy. Furthermore, they have provided practical guidance on how to manage AF in ibrutinib-treated patients.
(BELG J HEMATOL 2021;12(4):155-64)
Read moreBJH - volume 8, issue Abstract Book BSTH, february 2017
M. Criel , B. Izzi , C. Vandenbriele MD, PhD, L. Liesenborghs , S. van Kerckhoven , M. Lox , K. Cludts , E. A.V. Jones , T. Vanassche MD, PhD, P. Verhamme MD, PhD, M. Hoylaerts
BJH - volume 6, issue Abstract Book BSTH, november 2015
C. Vandenbriele MD, PhD, A. Kauskot , I. Vandersmissen , M. Criel , R. Geenens , S. Craps , A. Luttun , S. Janssens , M.F. Hoylaerts , P. Verhamme MD, PhD
BJH - volume 6, issue Abstract Book BSTH, november 2015
C. Vandenbriele MD, PhD, Y. Sun , M. Criel , K. Cludts , S. van Kerckhoven , B. Izzi , T. Vanassche MD, PhD, P. Verhamme MD, PhD, M.F. Hoylaerts
BJH - 2014, issue Abstract Book BSTH, november 2014
C. Vandenbriele MD, PhD, T. Vanassche MD, PhD, M. Peetermans , P. Verhamme MD, PhD, K. Peerlinck MD, PhD
BJH - 2014, issue Abstract Book BSTH, november 2014
Y. Sun , C. Vandenbriele MD, PhD, A. Kauskot , P. Verhamme MD, PhD, M.F. Hoylaerts , G.J. Wright
Top
